Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19741507 | 1.00 | AR (1.00) | ARPGRCYP3A4 | |
| SCHEMBL29504174 | 1.00 | AR (1.00) | ARPGRCYP3A4 | |
| SCHEMBL14086875 | 0.89 | AR (0.80) | ARPGRCYP3A4 | |
| SCHEMBL13244698 | 0.89 | AR (0.80) | ARPGRCYP3A4 | |
| SCHEMBL8409323 | 0.89 | AR (0.80) | ARPGRCYP3A4 | |
| SCHEMBL14086873 | 0.89 | AR (0.80) | ARPGRCYP3A4 | |
| SCHEMBL14086878 | 0.88 | AR (0.79) | ARPGRCYP3A4 | |
| SCHEMBL5178725 | 0.88 | AR (0.79) | ARPGRCYP3A4 | |
| SCHEMBL2641121 | 0.88 | AR (0.79) | ARPGRCYP3A4 | |
| SCHEMBL14086876 | 0.88 | AR (0.83) | ARPGRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-10-29 | — | — | US | disclosed |
| CN-117751099-A | Amide compound and application thereof | 中国药科大学 | 2024-03-22 | — | — | CN | disclosed |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | UNIV TENNESSEE RES FOUND (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-04-13 | — | — | US | disclosed |
| CN-115701991-A | Pyrazolylpropionamide compounds and their use for treating prostate cancer | 田纳西大学研究基金会 | 2023-02-14 | — | — | CN | disclosed |
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | Oncternal Therapeutics, Inc. | 2023-02-09 | — | — | US | disclosed |
| WO-2004062612-A2 | LARGE-SCALE SYNTHESIS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS | GTX INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004035736-A2 | HALOGENATED SELECTIVE ANDROGEN RECEPTOR MODULATORS AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-04-29 | — | — | WO | disclosed |
| CN-1471508-A | Selective androgen receptor modulators and methods of use thereof | ��ѧ�о��� | 2004-01-28 | — | — | CN | disclosed |
| US-20040014975-A1 | Synthesis of selective androgen receptor modulators | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, THE | 2004-01-22 | — | — | US | disclosed |
| US-20030232792-A1 | Selective androgen receptor modulators and methods of use thereof | TENNESSEE RESEARCH CORPORATION, THE UNIVERSITY OF | 2003-12-18 | — | — | US | disclosed |
| US-20030225040-A1 | Selective androgen receptor modulators and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2003-12-04 | — | — | US | disclosed |
| US-6569896-B2 | Useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-6492554-B2 | SUBSTITUTED ALPHA-HYDROXYISOBUTYRANILIDES; SUPPRESSING SPERMATOGENESIS; HORMONE THERAPY | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION | 2002-12-10 | — | — | US | disclosed |
| US-20020099036-A1 | Selective androgen receptor modulators and methods of use thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2002-07-25 | — | — | US | disclosed |
| US-20020099096-A1 | Selective androgen receptor modulators and methods of use thereof | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION, THE | 2002-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232792-A1 | Selective androgen receptor modulators and methods of use thereof | CYP19A1, AR, SHBG | AR 2/4885PGR 68/4885CYP3A4 455/4885 |
| US-20030225040-A1 | Selective androgen receptor modulators and methods of use thereof | CYP19A1, SHBG, FSHR | AR 4/4885PGR 86/4885CYP3A4 388/4885 |
| US-20230041951-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, AHR, BRDT | AR 1/4885PGR 601/4885CYP3A4 1195/4885 |
| US-11648234-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use | AR, BRCA1, FSHR | AR 1/4885PGR 115/4885CYP3A4 2397/4885 |
| US-20020099096-A1 | Selective androgen receptor modulators and methods of use thereof | AR, GNRHR, SHBG | AR 1/4885PGR 20/4885CYP3A4 538/4885 |
| US-12215086-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, BRCA1, AHR | AR 1/4885PGR 43/4885CYP3A4 940/4885 |
| US-12128026-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885PGR 601/4885CYP3A4 1195/4885 |
| US-20020099036-A1 | Selective androgen receptor modulators and methods of use thereof | AR, SHBG, FSHR | AR 1/4885PGR 104/4885CYP3A4 503/4885 |
| US-20230146829-A1 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | AR, BRCA1, FSHR | AR 1/4885PGR 103/4885CYP3A4 2032/4885 |
| US-20230115515-A1 | PYRAZOLYLPROPANAMIDE COMPOUNDS AND USES THEREOF FOR TREATMENT OF PROSTATE CANCER | AR, KLK3, ACP3 | AR 1/4885PGR 286/4885CYP3A4 300/4885 |
| US-11873282-B2 | Selective androgen receptor degrader (SARD) ligands and methods of use thereof | AR, AHR, BRDT | AR 1/4885PGR 601/4885CYP3A4 1195/4885 |
| US-20040014975-A1 | Synthesis of selective androgen receptor modulators | AR, CYP19A1, SHBG | AR 1/4885PGR 90/4885CYP3A4 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.